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We agree with the excellent summary provided by Reves and Benjamin of the important, but 
insufficient, progress toward tuberculosis (TB) elimination (<1 case per million population) 
in the United States over the past two decades. Furthermore, we concur with the need to 
advance the argument in favor of additional investments required to eliminate TB by 
providing an estimate of future expected benefits.
While we did not model future projected savings in our report,1 we have undertaken 
relatively simple retrospective modeling to estimate the reduction in TB cases and societal 
benefits had TB elimination been achieved in 1995 and sustained through 2014. From this 
we estimate that during 1995–2014 from 430 397 to 604 494 TB cases would have been 
averted (Figure 1), at estimated benefits of US $19.9 billion to $27.7 billion, including the 
value of deaths prevented and the costs to treat drug-resistant TB disease (Figure 2). 
Projected cases averted and cost savings for two decades into the future would also be 
anticipated to be substantial, although somewhat less, because even with a flat case rate the 
projected case counts for the next two decades would be less than those that actually 
occurred between 1995 and 2014.
To assist in the direction of US TB elimination efforts, a newly formed consortium funded 
by the US Centers for Disease Control and Prevention (The NCHHSTP Epidemiologic and 
Economic Modeling Agreement) is designing more detailed and robust models. This 
consortium includes collaborators from the Johns Hopkins University with Emory 
University, the Harvard University, and the University of California at San Francisco. These 
investigators’ models will calibrate to historical TB data and estimate future TB incidence 
and costs according to changes in various programmatic efforts to achieve TB elimination.
The results of this effort are expected to inform and identify activities that could be 
prioritized and targeted to achieve TB elimination in the shortest period of time and using 
the least amount of resources. Such ongoing modeling results should be published within the 
next 2 years, if not sooner. Moreover, global collaborations are also taking place to 
implement clinical trials and data analyses to identify optimized regimens for the treatment 
of persons with drug-resistant disease and latent tuberculous infection caused by drug-
resistant strains. These efforts have become indispensable to address the increasing global 
burden, challenge, and cost of drug-resistant TB—as well as its prevention.
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TB cases averted in the United States, 1995–2014, if elimination (<1 case per million 
population) achieved and sustained 1995–2014, by scenarios and model.1
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TB costs averted in the United States, 1995–2014, if elimination (<1 case per million 
population) achieved and sustained 1995–2014, by scenarios and model.1
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